I agree with this scenario. IMO no big pharma will license or partner without controlling interest, especially based on LP's past behavior. And, LP clearly haws had no interest in giving up control. I believe the price of deal changed after SNO. Any prior negotiations were redrawn with higher purchase prices after SNO. This is what I believe she meant in the late 10-Q filing...ongoing negotiations, which if completed prior to SNO and before new data release would have been at one price. Now, they restart talks with a higher level of confidence in achieving success in trial. My guess is a complete buyout, either at todays valuation (?) after SNO or at a substantially higher price if based on top line release. December buyout at a valuation based on fully diluted shares and a $6 purchase price ($7.2 billion)..IMO.
News 
Market Data 
Discover 
AI
